Literature DB >> 18034825

Ursodeoxycholic acid: Mechanism of action and novel clinical applications.

Tadashi Ikegami1, Yasushi Matsuzaki.   

Abstract

Ursodeoxycholic acid (UDCA) is used in the treatment of cholestatic liver diseases, gallstone dissolution, and for patients with hepatitis C virus infection to ameliorate elevated alanine aminotransferase levels. The efficacy of UDCA treatment has been debated and the mechanisms of action in humans have still not defined. Suggested mechanisms include the improvement of bile acid transport and/or detoxification, cytoprotection, and anti-apoptotic effects. In this review, we summarize the proposed molecular mechanisms for the action of UDCA, especially in hepatocytes, and also discuss the putative future clinical usage of this unique drug.

Entities:  

Year:  2007        PMID： 18034825     DOI： 10.1111/j.1872-034X.2007.00297.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


  31 in total

1.  Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction.

Authors:  Asli F Ceylan-Isik; Nair Sreejayan; Jun Ren
Journal:  J Mol Cell Cardiol       Date:  2010-10-28       Impact factor: 5.000

Review 2.  Effect of asymmetric dimethylarginine (ADMA) on heart failure development.

Authors:  Xiaoyu Liu; Lei Hou; Dachun Xu; Angela Chen; Liuqing Yang; Yan Zhuang; Yawei Xu; John T Fassett; Yingjie Chen
Journal:  Nitric Oxide       Date:  2016-02-24       Impact factor: 4.427

3.  No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.

Authors:  Xiaoqiang Xiang; Juha Vakkilainen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2011-06-08       Impact factor: 2.953

Review 4.  Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review.

Authors:  David Q-H Wang; Martin C Carey
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.

Authors:  Kenichi Hosonuma; Ken Sato; Yuichi Yamazaki; Masatoshi Yanagisawa; Hiroaki Hashizume; Norio Horiguchi; Satoru Kakizaki; Motoyasu Kusano; Masanobu Yamada
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

6.  Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages.

Authors:  Yinan Hua; Machender R Kandadi; Meijun Zhu; Jun Ren; Nair Sreejayan
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

Review 7.  Hepatotoxic herbs: will injury mechanisms guide treatment strategies?

Authors:  Thomas H Frazier; Kristine J Krueger
Journal:  Curr Gastroenterol Rep       Date:  2009-08

8.  Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.

Authors:  Jenessa A Winston; Alissa J Rivera; Jingwei Cai; Rajani Thanissery; Stephanie A Montgomery; Andrew D Patterson; Casey M Theriot
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

9.  Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells.

Authors:  Tatehiro Kagawa; Reiko Orii; Shunji Hirose; Yoshitaka Arase; Koichi Shiraishi; Akiko Mizutani; Hidekazu Tsukamoto; Tetsuya Mine
Journal:  J Gastroenterol       Date:  2013-05-31       Impact factor: 7.527

10.  Bile acids in treatment of ocular disease.

Authors:  Jeffrey H Boatright; John M Nickerson; Anisha G Moring; Machelle T Pardue
Journal:  J Ocul Biol Dis Infor       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.